Rapid Micro Biosystems, Inc. Class A Common Stock

Rapid Micro Biosystems (Nasdaq: RPID) announced it will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The company provides automation solutions for pharmaceutical manufacturing and quality control testing, with its flagship Growth Direct system modernizing microbial quality control workflows. The presentation w...

Rapid Micro Biosystems reported Q3 2025 revenue of $7.8 million, a 3% growth from 2024. The company received a record multi-system order from a Top 20 global biopharma customer and raised its full-year revenue guidance to at least $33.0 million.

Rapid Micro Biosystems, Inc. (RPID) announced the grant of 160,000 restricted stock units and 250,000 stock options to a new employee as a material inducement to employment. The equity awards are subject to vesting conditions and were approved by the company's independent directors.

Rapid Micro Biosystems, an innovative life sciences technology company, has welcomed Dr. Dafni Bika to its Board of Directors. Dr. Bika brings over 25 years of experience in pharmaceutical development and manufacturing, which will contribute to the company's growth as it continues to establish its Growth Direct platform as the industry standard f...

The pharmaceutical sterility testing market is growing rapidly due to increasing demand for safe and effective pharmaceutical products, advancements in testing technologies, and the rising focus on biopharmaceuticals. The market is expected to reach $3.79 billion by 2032, driven by stringent regulations, the need for sterility testing in new ther...